Sequent Medical, Inc. has gained the CE mark for the SL (“Single Layer”) family of WEB® Aneurysm Embolization Devices, and has commenced a controlled release of these new models in select neurovascular centers in Europe. The SL family offers a lower profile and superior navigability that Sequent says will enable physicians to treat a broader range of aneurysms with the WEB platform.
Sequent’s WEB family of low porosity intrasaccular neurovascular embolization devices are designed to bridge the neck of a ruptured or unruptured intracranial aneurysm and to promote rapid, peri-procedural stasis.
The devices enable physicians to treat a broad range of intracranial aneurysms with the familiarity of an intrasaccular approach while using established biomaterials.
The SL configurations utilise Sequent Medical’s proprietary MicroBrai™ technology, a dense mesh constructed from a large number of extremely fine Nitinol wires. Unlike conventional medical braids, MicroBraid features a mix of wire diameters and high wire counts to achieve a tailored balance of compliance, porosity and profile across device sizes.
The SL family consists of two separate product configurations, the WEB SL and WEB SLS, each with a distinct shape designed to accommodate varying aneurysm morphologies. Both configurations are available in multiple sizes ranging from 4-11 mm and are designed for delivery through Sequent Medical’s VIA microcatheters.
“Sequent Medical has responded to physicians’ requests in developing the WEB SL configurations,” said Prof Laurent Pierot, MD PhD, Head of the Department of Radiology, Maison Blanche Hospital, Reims, France. “The SL family promises to expand the range of aneurysms physicians can treat with the WEB while continuing to offer the familiar straightforward procedure we’ve come to value with the WEB DL.”
“Combined with our recently introduced VIA microcatheter line, the introduction of the SL products demonstrates Sequent Medical’s ongoing commitment to developing a broad portfolio of innovative catheter-based technologies for neurovascular specialists and their patients,” said Tom Wilder, President and Chief Executive Officer.
Source: Sequent Medical, Inc.